JP2011510327A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510327A5
JP2011510327A5 JP2010544349A JP2010544349A JP2011510327A5 JP 2011510327 A5 JP2011510327 A5 JP 2011510327A5 JP 2010544349 A JP2010544349 A JP 2010544349A JP 2010544349 A JP2010544349 A JP 2010544349A JP 2011510327 A5 JP2011510327 A5 JP 2011510327A5
Authority
JP
Japan
Prior art keywords
predetermined value
subject
gelsolin
plasma
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010544349A
Other languages
English (en)
Japanese (ja)
Other versions
JP5778425B2 (ja
JP2011510327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000452 external-priority patent/WO2009094194A2/en
Publication of JP2011510327A publication Critical patent/JP2011510327A/ja
Publication of JP2011510327A5 publication Critical patent/JP2011510327A5/ja
Application granted granted Critical
Publication of JP5778425B2 publication Critical patent/JP5778425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010544349A 2008-01-25 2009-01-23 腎不全におけるゲルソリンの診断的および治療的使用 Active JP5778425B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2378908P 2008-01-25 2008-01-25
US61/023,789 2008-01-25
PCT/US2009/000452 WO2009094194A2 (en) 2008-01-25 2009-01-23 Diagnostic and therapeutic uses of gelsolin in renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015005994A Division JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Publications (3)

Publication Number Publication Date
JP2011510327A JP2011510327A (ja) 2011-03-31
JP2011510327A5 true JP2011510327A5 (cg-RX-API-DMAC10.html) 2013-08-29
JP5778425B2 JP5778425B2 (ja) 2015-09-16

Family

ID=40901583

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010544349A Active JP5778425B2 (ja) 2008-01-25 2009-01-23 腎不全におけるゲルソリンの診断的および治療的使用
JP2015005994A Active JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015005994A Active JP6042915B2 (ja) 2008-01-25 2015-01-15 腎不全におけるゲルソリンの診断的および治療的使用

Country Status (10)

Country Link
US (2) US9575072B2 (cg-RX-API-DMAC10.html)
EP (2) EP2708603B1 (cg-RX-API-DMAC10.html)
JP (2) JP5778425B2 (cg-RX-API-DMAC10.html)
CA (2) CA3080273C (cg-RX-API-DMAC10.html)
DK (2) DK2250280T3 (cg-RX-API-DMAC10.html)
ES (2) ES2634263T3 (cg-RX-API-DMAC10.html)
HU (1) HUE032875T2 (cg-RX-API-DMAC10.html)
PL (2) PL2250280T3 (cg-RX-API-DMAC10.html)
PT (2) PT2708603T (cg-RX-API-DMAC10.html)
WO (1) WO2009094194A2 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CN1980694B (zh) * 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
JP2009530613A (ja) * 2006-03-15 2009-08-27 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
US9000134B2 (en) 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
EP2708603B1 (en) 2008-01-25 2017-04-19 The General Hospital Corporation Diagnostic and therapeutic uses of gelsolin in renal failure
US20100049672A1 (en) * 2008-08-25 2010-02-25 Critical Biologics Corporation Methods for Reducing Sample Size of Clinical Trials
ES2356217B1 (es) * 2009-08-04 2012-02-13 Universidad De Salamanca Método para la detección de daño renal.
TW201601741A (zh) * 2013-09-09 2016-01-16 品特生物療法有限公司 用於治療ｅｓｒｄ病患之ｐｅｗ的肌肉生長抑制素拮抗劑
CN104004780A (zh) * 2014-06-17 2014-08-27 南京大学 一种人胞质凝溶胶蛋白的表达纯化方法
WO2016033187A1 (en) * 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
JP6947449B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
AU2020296862B2 (en) * 2019-06-21 2025-10-09 Bioaegis Therapeutics Inc. Compositions and synergistic methods for treating infections
PL4146244T3 (pl) * 2020-05-04 2026-04-07 Bioaegis Therapeutics Inc. Kompozycje zawierające gelsolinę do leczenia osłabienia
AU2024317666A1 (en) * 2023-07-28 2026-01-15 Societe Des Produits Nestle Sa Compositions and methods for diagnosing and/or treating chronic kidney disease

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) * 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
ES2124702T3 (es) 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
CA2063593A1 (en) 1990-05-04 1991-11-05 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5360350A (en) * 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
CA2141600A1 (en) 1992-08-03 1994-02-17 Richard U. Margolis Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
EP0675967A4 (en) 1992-10-01 1999-04-28 Gen Hospital Corp Functional assay for tumor suppressor genes.
US5830436A (en) 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5563153A (en) 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5804427A (en) * 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) * 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
AU3817497A (en) 1996-07-30 1998-02-20 Biogen, Inc. Production of recombinant plasma gelsolin containing a disulfide bond
DK0941108T3 (da) * 1996-12-04 2002-11-18 Renovo Ltd Sårheling og behandling af fibrose
WO1998043630A1 (en) * 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
IL148841A0 (en) 1999-10-06 2002-09-12 Basf Ag INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αvβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
WO2002059604A2 (en) 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
NZ528076A (en) 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
DE60233414D1 (de) 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
CA2458677A1 (en) 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
US20080051348A1 (en) 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
EP2266595A3 (en) 2002-02-06 2011-07-06 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2003088811A2 (en) 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
US20050048574A1 (en) 2003-03-14 2005-03-03 Kantor Aaron B. Biomarkers for diagnosing rheumatoid arthritis
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CA2550833A1 (en) 2003-12-22 2005-07-14 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
ES2541683T3 (es) 2004-02-27 2015-07-23 F. Hoffmann-La Roche Ag Método para evaluar la artritis reumatoide mediante la medición del factor reumatoide y la interleuquina-6
CN1980694B (zh) * 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
SG183012A1 (en) 2004-06-04 2012-08-30 Genentech Inc Method for treating multiple sclerosis
DK1929297T3 (da) 2005-09-29 2013-03-04 Caprion Proteomics Usa Llc Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
JP2009530613A (ja) * 2006-03-15 2009-08-27 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
EP2708603B1 (en) 2008-01-25 2017-04-19 The General Hospital Corporation Diagnostic and therapeutic uses of gelsolin in renal failure
KR101568323B1 (ko) 2014-01-08 2015-11-12 한국원자력의학원 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease

Similar Documents

Publication Publication Date Title
Zhang et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A (H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity
Kedzierski et al. Suppressor of cytokine signaling (SOCS) 5 ameliorates influenza infection via inhibition of EGFR signaling
Gao et al. Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis
Harris et al. Double-stranded RNA induces molecular and inflammatory signatures that are directly relevant to COPD
Ramsey et al. In utero exposure to arsenic alters lung development and genes related to immune and mucociliary function in mice
Harris et al. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response
Hoffman et al. Protein disulfide isomerase–endoplasmic reticulum resident protein 57 regulates allergen-induced airways inflammation, fibrosis, and hyperresponsiveness
US20170189483A1 (en) Diagnostic and therapeutic uses of gelsolin in renal failure
Belknap et al. The challenges of interstitial cystitis: current status and future prospects
WO2012041334A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Coudroy et al. Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis
WO2013143548A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Shaker et al. Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients
Song et al. C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury
Stefaniak et al. Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation
Takase et al. Evaluation of risk for incident hypertension using glomerular filtration rate in the normotensive general population
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
García‐Gimenez et al. Circulating histones as clinical biomarkers in critically ill conditions
Luna et al. Senolytic treatment attenuates immune cell infiltration without improving IAV outcomes in aged mice
Zhang et al. Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF-κB signaling pathway.
Parenica et al. Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality
Ganesh et al. Correlation of urinary nephrin with albubinuria to predict early onset of nephropathy in patients with type 2 diabetes mellitus
WO2019023181A1 (en) METHODS OF TREATING INFLUENZA-RELATED VIRAL PNEUMONIA
Chuang et al. Anti-CCR3 monoclonal antibody inhibits eosinophil infiltration in Angiostrongylus cantonensis-infected ICR mice
Chen et al. Development of a non-infectious rat model of acute exacerbation of idiopathic pulmonary fibrosis